Navigation Links
Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Date:6/25/2008

t of acne, we intend to advance SL017 PDT for one or more clinical indications," stated Thomas Woo, M.Sc., Vice President for Drug Development of Quest.

The Principal Investigator for Quest's Phase I/II hair removal trial is Dr. Robert Bissonnette, M.D., President of Innovaderm Research in Montreal.

About SL017: SL017 is a proprietary, non-toxic drug that, once applied to a target area and activated by light, is transformed into a potent cytotoxic agent that selectively destroys targeted tissue. Using this process, known as photodynamic therapy (PDT), SL017 can be applied to treat a variety of skin conditions, including hair removal, actinic keratosis and acne. The safety and potential utility of SL017 for the treatment of actinic keratosis has been demonstrated in a Phase I Clinical Study.

About Quest PharmaTech Inc.: Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform.

"TSX Venture Exchange has neither approved nor disapproved of the

information herein."


'/>"/>
SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release fourth quarter and ... March 10, 2015 after the close of the U.S. ... and webcast on Tuesday, March 10, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:3/2/2015)... Outside GC, the leading provider of on-demand, in-house ... Casey as a member of the firm, further strengthening ... , Debbie has spent over 20 years in the ... North America in both legal and business capacities. ... Outside GC’s growing list of healthcare clients, with a ...
(Date:2/27/2015)... and SUMMERLAND, British Columbia , Feb. ... XON ), a leader in synthetic biology, today ... Okanagan Specialty Fruits (OSF), the pioneering agricultural company ... world,s first non-browning apple. Through the acquisition, Intrexon expands ... is more appetizing and convenient for consumers while providing ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... Realty Trust, Inc.,(NYSE: BMR ) today announced the tax treatment of its 2007 distributions as,follows:, ... CUSIP: 09063H107 ... Total ... Taxable Ordinary Date Date ...
... Inc.,(NYSE: BMR ) today announced it will report results ... the market closes on Thursday,February 28, 2008., Alan D. ... Officer, will host an investor conference call at 10:00,a.m. Pacific ... results and operations for the year., The call will ...
... , RICHMOND, VA, January 29 ... interview with Insmed Therapeutic Proteins President,Steve Glover ... industry is good for,patients and can stem ... from biotechnology. The American Magazine is the ...
Cached Biology Technology:BioMed Realty Trust Announces Tax Treatment of 2007 Distributions 2BioMed Realty Trust Announces Tax Treatment of 2007 Distributions 3BioMed Realty Trust To Report 2007 Fourth Quarter and Year-End Results 2Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine 2Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine 3
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... , Every year the approach of flu season sets off ... are many different strains of flu and they vary from ... educated guess and tell manufacturers which variants of the flu ... works, flu-related illnesses can kill 3,000 to 49,000 Americans annually, ...
... the Polytechnic Institute of New York University (NYU-Poly) and ... carrier in their lab that is five times more ... delivery methodsreagent vectors. This novel complex is a peptide-polymer ... are used to carry DNA into cells. ...
... is a devastating illness that gradually robs sufferers of muscle ... drug available to treat the disease extends life spans by ... study published in Nature Genetics , University of Pennsylvania ... which ALS acts. Working with a powerful fruit fly model ...
Cached Biology News:Stanford researchers take a step toward developing a 'universal' flu vaccine 2Stanford researchers take a step toward developing a 'universal' flu vaccine 3Stanford researchers take a step toward developing a 'universal' flu vaccine 4Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells 2Penn-led team reduces toxicity associated with Lou Gehrig's disease in animal models 2Penn-led team reduces toxicity associated with Lou Gehrig's disease in animal models 3Penn-led team reduces toxicity associated with Lou Gehrig's disease in animal models 4